CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification.
AIDS/HIV
Adaptive immunity
T cells
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
15 04 2021
15 04 2021
Historique:
received:
25
06
2020
accepted:
23
02
2021
pubmed:
26
2
2021
medline:
29
9
2021
entrez:
25
2
2021
Statut:
ppublish
Résumé
To define the contribution of CD8+ T cell responses to control of SIV reactivation during and following antiretroviral therapy (ART), we determined the effect of long-term CD8+ T cell depletion using a rhesusized anti-CD8β monoclonal antibody on barcoded SIVmac239 dynamics on stable ART and after ART cessation in rhesus macaques (RMs). Among the RMs with full CD8+ T cell depletion in both blood and tissue, there were no significant differences in the frequency of viral blips in plasma, the number of SIV RNA+ cells and the average number of RNA copies/infected cell in tissue, and levels of cell-associated SIV RNA and DNA in blood and tissue relative to control-treated RMs during ART. Upon ART cessation, both CD8+ T cell-depleted and control RMs rebounded in fewer than 12 days, with no difference in the time to viral rebound or in either the number or growth rate of rebounding SIVmac239M barcode clonotypes. However, effectively CD8+ T cell-depleted RMs showed a stable, approximately 2-log increase in post-ART plasma viremia relative to controls. These results indicate that while potent antiviral CD8+ T cell responses can develop during ART-suppressed SIV infection, these responses effectively intercept post-ART SIV rebound only after systemic viral replication, too late to limit reactivation frequency or the early spread of reactivating SIV reservoirs.
Identifiants
pubmed: 33630764
pii: 141677
doi: 10.1172/JCI141677
pmc: PMC8262469
doi:
pii:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : P51 OD011092
Pays : United States
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NIH HHS
ID : S10 OD025002
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI126611
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI124377
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI054292
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Références
Nat Med. 2009 Mar;15(3):293-9
pubmed: 19219024
Nature. 2013 Oct 3;502(7469):100-4
pubmed: 24025770
Curr Top Microbiol Immunol. 2018;417:69-109
pubmed: 29026923
Immunity. 2007 Sep;27(3):406-16
pubmed: 17892849
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
Nat Med. 2018 Sep;24(9):1430-1440
pubmed: 30082858
J Exp Med. 2009 Jul 6;206(7):1575-88
pubmed: 19546246
AIDS. 2002 Jan 25;16(2):161-70
pubmed: 11807299
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
AIDS Res Hum Retroviruses. 2016 Feb;32(2):163-8
pubmed: 26150024
J Virol. 2014 Jul;88(14):8077-90
pubmed: 24807714
Immunol Rev. 2007 Feb;215:178-88
pubmed: 17291288
Elife. 2019 Oct 25;8:
pubmed: 31650954
J Exp Med. 2012 Apr 9;209(4):641-51
pubmed: 22451717
J Virol. 2001 Jul;75(14):6508-16
pubmed: 11413318
Nat Rev Immunol. 2013 Jul;13(7):487-98
pubmed: 23797064
Cell Host Microbe. 2019 Jul 10;26(1):73-85.e4
pubmed: 31295427
Nature. 1998 Dec 17;396(6712):690-5
pubmed: 9872319
J Virol. 2019 Dec 12;94(1):
pubmed: 31597757
Nature. 2011 May 26;473(7348):523-7
pubmed: 21562493
PLoS Pathog. 2017 May 4;13(5):e1006359
pubmed: 28472156
Nature. 2020 Feb;578(7796):E21
pubmed: 32015546
Nature. 2017 Mar 23;543(7646):559-563
pubmed: 28289286
Nature. 2020 Feb;578(7793):154-159
pubmed: 31969705
Immunity. 2014 Sep 18;41(3):451-464
pubmed: 25220211
Pathog Immun. 2016 Spring;1(1):68-106
pubmed: 27430032
Nature. 2016 Dec 8;540(7632):284-287
pubmed: 27841870
Nat Med. 2020 Apr;26(4):519-528
pubmed: 32284611
Front Immunol. 2019 Sep 10;10:2109
pubmed: 31552045
Annu Rev Med. 2012;63:95-111
pubmed: 21942424
Science. 1999 Feb 5;283(5403):857-60
pubmed: 9933172
J Exp Med. 2007 Sep 3;204(9):2171-85
pubmed: 17724130
Immunity. 2018 May 15;48(5):872-895
pubmed: 29768175
Nature. 2017 Jul 6;547(7661):123-124
pubmed: 28636599
Nature. 2015 Jan 15;517(7534):381-5
pubmed: 25561180
J Virol. 2007 Aug;81(16):8827-32
pubmed: 17537848
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):E3413-22
pubmed: 27247400
J Clin Invest. 2018 Feb 1;128(2):876-889
pubmed: 29355843
J Immunol. 2008 Jan 1;180(1):350-60
pubmed: 18097036
J Virol. 2003 Feb;77(4):2736-40
pubmed: 12552014
Nat Rev Immunol. 2004 Aug;4(8):630-40
pubmed: 15286729
J Clin Invest. 2016 Feb;126(2):455-63
pubmed: 26731469
PLoS Pathog. 2018 Oct 11;14(10):e1007350
pubmed: 30308068
Am J Pathol. 2008 Jun;172(6):1603-16
pubmed: 18467697
Nat Med. 2015 Feb;21(2):132-9
pubmed: 25599132
Lab Anim (NY). 2017 May 22;46(6):259-270
pubmed: 28530684